23andMe Sets New Auction With $305 Million New Bid From Ex-CEO

23andMe will hold a second auction for its DNA data assets after its previous auction outcome was challenged in court. The opening bid is $305 million from a group led by former CEO Anne Wojcicki, surpassing Regeneron Pharmaceuticals' prior winning bid by nearly $50 million.

Analysis

Bankrupt genetic analysis company 23andMe is advancing to a second auction for its significant DNA data assets, with a new opening bid of $305 million submitted by a group led by its former CEO, Anne Wojcicki. This revised offer is nearly $50 million higher than Regeneron Pharmaceuticals' (REGN) previous winning bid from the first auction, the outcome of which was successfully challenged in court by Wojcicki. This development underscores the high strategic value placed on 23andMe's extensive genetic database, even amidst bankruptcy proceedings, and introduces further complexity into the M&A process. For Regeneron Pharmaceuticals, this represents a setback, as reflected by a negative ticker sentiment score of -0.4, potentially forcing it to consider a higher counter-offer or abandon its pursuit of these specific assets. The overall market sentiment surrounding this news is 'mixed' (sentiment score 0.15) with a 'low' market impact score (0.25), indicating that while the event is pivotal for the entities directly involved and the genetic data sector, its broader market implications are currently limited. The situation highlights active themes of M&A and restructuring, legal and litigation battles, and the inherent value and risks associated with large-scale data in the healthcare and biotech industries, particularly concerning company fundamentals and governance.

Key Decisions for Investors

• Investors in Regeneron Pharmaceuticals (REGN) should closely monitor for any further announcements regarding a potential counter-bid or revised strategy for acquiring data assets, as the current situation presents a challenge to its previous acquisition effort.
• The increased valuation for 23andMe's data through this new bid, despite its bankruptcy, may signal broader positive valuation trends for companies possessing unique and extensive datasets, particularly in the biotech and personalized medicine sectors.
• Consider the heightened legal and execution risks in M&A transactions involving valuable but sensitive data assets, as demonstrated by the successful legal challenge and subsequent re-auction process, which can impact timelines and ultimate deal outcomes.